JP7735306B2 - マスクされたｉｌ－２サイトカイン及びその切断産物 - Google Patents

マスクされたｉｌ－２サイトカイン及びその切断産物

Info

Publication number
JP7735306B2
JP7735306B2 JP2022560205A JP2022560205A JP7735306B2 JP 7735306 B2 JP7735306 B2 JP 7735306B2 JP 2022560205 A JP2022560205 A JP 2022560205A JP 2022560205 A JP2022560205 A JP 2022560205A JP 7735306 B2 JP7735306 B2 JP 7735306B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
cytokine
domain
masked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022560205A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021202675A5 (https=
JP2023520517A5 (https=
JP2023520517A (ja
Inventor
ラファエル ローゼンフェルド，
ウグル エスキオチャク，
ファーウェイ チウ，
パーカー ジョンソン，
カート アレン ジェンキンス，
マガリ ペデルゾリ－リベイル，
ディラージ スィング トマル，
レベカ カイ オドンネル，
Original Assignee
エクシリオ デベロップメント， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクシリオ デベロップメント， インコーポレイテッド filed Critical エクシリオ デベロップメント， インコーポレイテッド
Publication of JP2023520517A publication Critical patent/JP2023520517A/ja
Publication of JPWO2021202675A5 publication Critical patent/JPWO2021202675A5/ja
Publication of JP2023520517A5 publication Critical patent/JP2023520517A5/ja
Application granted granted Critical
Publication of JP7735306B2 publication Critical patent/JP7735306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
JP2022560205A 2020-04-01 2021-03-31 マスクされたｉｌ－２サイトカイン及びその切断産物 Active JP7735306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003824P 2020-04-01 2020-04-01
US63/003,824 2020-04-01
US202063118571P 2020-11-25 2020-11-25
US63/118,571 2020-11-25
PCT/US2021/025103 WO2021202675A1 (en) 2020-04-01 2021-03-31 Masked il-2 cytokines and their cleavage products

Publications (4)

Publication Number Publication Date
JP2023520517A JP2023520517A (ja) 2023-05-17
JPWO2021202675A5 JPWO2021202675A5 (https=) 2024-04-10
JP2023520517A5 JP2023520517A5 (https=) 2024-04-10
JP7735306B2 true JP7735306B2 (ja) 2025-09-08

Family

ID=77928454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560205A Active JP7735306B2 (ja) 2020-04-01 2021-03-31 マスクされたｉｌ－２サイトカイン及びその切断産物

Country Status (13)

Country Link
US (1) US20230151072A1 (https=)
EP (1) EP4126247A4 (https=)
JP (1) JP7735306B2 (https=)
KR (1) KR20220161404A (https=)
CN (1) CN115942976A (https=)
AU (1) AU2021245922A1 (https=)
BR (1) BR112022019689A2 (https=)
CA (1) CA3172649A1 (https=)
IL (1) IL296915A (https=)
MX (1) MX2022012311A (https=)
PH (1) PH12022552627A1 (https=)
TW (1) TW202204388A (https=)
WO (1) WO2021202675A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021254283B2 (en) * 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2024511387A (ja) 2021-03-16 2024-03-13 シートムエックス セラピューティクス，インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
MX2024010488A (es) * 2022-02-28 2024-09-05 Xilio Dev Inc Citocinas dirigidas y metodos de uso de estas.
WO2023164286A1 (en) * 2022-02-28 2023-08-31 Xilio Development, Inc. Engineered cd122 compositions and methods thereof
KR20250039361A (ko) * 2022-07-15 2025-03-20 실리오 디벨럽먼트, 인크. 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥（香港）有限公司 Ｋｌｋ１融合蛋白質的製備方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025049948A1 (en) * 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218993A (zh) 2018-01-05 2018-06-29 李华顺 一种以robo1为靶点的双特异性抗体及其制备和应用
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP2022533254A (ja) 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EP2882775B1 (en) * 2012-08-09 2018-02-14 Roche Glycart AG Asgpr antibodies and uses thereof
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CN112867503A (zh) * 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108218993A (zh) 2018-01-05 2018-06-29 李华顺 一种以robo1为靶点的双特异性抗体及其制备和应用
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド
JP2022533254A (ja) 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法

Also Published As

Publication number Publication date
MX2022012311A (es) 2023-01-05
AU2021245922A1 (en) 2022-10-13
EP4126247A1 (en) 2023-02-08
PH12022552627A1 (en) 2023-01-04
US20230151072A1 (en) 2023-05-18
BR112022019689A2 (pt) 2022-12-20
EP4126247A4 (en) 2024-04-24
CN115942976A (zh) 2023-04-07
WO2021202675A1 (en) 2021-10-07
KR20220161404A (ko) 2022-12-06
CA3172649A1 (en) 2021-10-07
TW202204388A (zh) 2022-02-01
JP2023520517A (ja) 2023-05-17
IL296915A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP7735306B2 (ja) マスクされたｉｌ－２サイトカイン及びその切断産物
JP7771076B2 (ja) マスクされたｉｌ－１２サイトカイン及びその切断産物
US11718655B2 (en) Masked interleukin-12 polypeptides
US20230331799A1 (en) Masked il-15 cytokines and their cleavage products
US12280120B2 (en) Tumor-specific cleavable linkers
US20260115302A1 (en) Tumor-specific cleavable linkers
HK40092028A (zh) 掩蔽的il-2细胞因子和其切割产物
HK40090912A (zh) 掩蔽的il-15细胞因子和其切割产物
EA049880B1 (ru) Маскированные цитокиновые полипептиды

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250827

R150 Certificate of patent or registration of utility model

Ref document number: 7735306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150